Compare Enphase Energy Inc (ENPH) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs TG Therapeutics Inc — how do they compare? Enphase Energy Inc trades at $41.07 (market cap $5.81B), while TG Therapeutics Inc trades at $54.87 (market cap $8.64B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals.
| ENPH | TGTX | |
|---|---|---|
Market Cap | $5.81B | $8.64B |
Sector | Technology | Health |
52-Week High | $72.33 | $59.06 |
52-Week Low | $26.12 | $26.39 |
Enterprise Value | $5.46B | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $41.59, down 7.55% in the past 24 hours, reflecting recent bearish pressure. The stock shows a mixed technical picture with support near $39 and resistance at $44, while fundamentals indicate solid profitability with a 44.23% gross margin and consistent earnings beats in recent quarters. Recent news highlights product expansions in Europe and Australia, alongside positive analyst coverage citing long-term tailwinds despite short-term challenges.
Outlook remains cautiously optimistic with a consensus price target of $42.79, slightly above current levels. Key opportunities include global product rollouts and high margins, but risks involve revenue volatility, competitive pressures, and ongoing legal scrutiny. Investors should weigh strong fundamentals against near-term stock weakness and market sentiment shifts.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
